Tianfang Pharmaceutical, a unit of Tongyong Technology China Pharmaceuticals, received an NMPA supplemental-approval notice for diclofenac sodium enteric-coated tablets after passing generic quality and efficacy consistency evaluation. Indications include inflammatory and degenerative rheumatic diseases, non-articular soft-tissue rheumatic pain, acute mild-to-moderate pain and acute gout attacks. The product is listed on China’s national reimbursement list (Category A).